Skip to content

Ribbon Bio vs Synbio Technologies

Ribbon Bio logo

Ribbon Bio

Synthetic DNA Built without Bacteria. At your Lab Bench

63 employees · est. 2018 · Vienna, Austria

VS
Synbio Technologies logo

Synbio Technologies

Changing the world, one sequence at a time

25 employees · est. 2013 · United States

Synbio Technologies is the older company (2018 vs 2013); Ribbon Bio is the larger of the two.

Side-by-Side Comparison

Ribbon Bio Synbio Technologies
Founded
2018 2013 older
Headquarters
Vienna, Austria United States
Employees
63 larger 25
Industry
Biotechnology Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series A Not tracked yet
Total Funding
$18.00M Not tracked yet
Funding Rounds
2 Not tracked yet
Services
Not tracked yet Comprehensive Gene Synthesis, Custom RNA and DNA Oligo Synthesis, Precision Gene Editing Solutions, Virus Packaging, Antibody Sequencing and Production, Custom Peptide Development, High-throughput Protein Expression, Bioinformatics and Sequence Analysis
Target Customers
Not tracked yet Biotech and Pharmaceutical Companies, Academic and Research Institutions, Clinical Laboratories, Healthcare and Medical Research Professionals, Synthetic Biology Startups
Taxonomy
BiotechDNA SynthesisMolecular BiologySynthetic BiologyBiopharmaceuticalTechnology +8 Synthetic Biology ServicesDNA SequencingDNA SynthesisDNA EngineeringPrecision MedicineProtein Production +9
Website
ribbonbio.com synbio-tech.com
Ribbon Bio logo

About Ribbon Bio

Ribbon Biolabs: Ribbon Biolabs, a biotech start-up founded in 2018 and headquartered in Austria, is revolutionizing DNA synthesis with its innovative approach. The company aims to develop a cost-efficient platform for error-proof DNA synthesis, enabling the production of long and complex DNA molecul...

Synbio Technologies logo

About Synbio Technologies

Synbio Technologies, established in 2013, is a pioneering company in the fields of Biotechnology, Health Care, and Pharmaceutical. Headquartered in the United States, the company is built on the vision of "Changing the world, one sequence at a time." With a comprehensive suite of synthetic biology...

Also comparing in this category

Comparing more than these two?

Get Ribbon Bio, Synbio Technologies and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Ribbon Bio compare?

A PDF of Ribbon Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Ribbon Bio was founded in 2018, based in Vienna, Austria, with 63 employees. Ribbon Biolabs: Ribbon Biolabs, a biotech start-up founded in 2018 and headquartered in Austria, is revolutionizing DNA synthesis with its innovative approach. The company aims to develop a cost-effic. Synbio Technologies was founded in 2013, based in United States, with 25 employees. Synbio Technologies, established in 2013, is a pioneering company in the fields of Biotechnology, Health Care, and Pharmaceutical. Headquartered in the United States, the company is built on the visio.
Ribbon Bio has raised $18.00M and Synbio Technologies no disclosed funding. Latest stage: Ribbon Bio Series A.
Both work in Biotechnology and list dna synthesis among their focus areas.

Compare Ribbon Bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Ribbon Bio on 5 Nov 2026, and Synbio Technologies on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout